Amicus Therapeutics has entered a collaboration with the Perelman School of Medicine at the University of Pennsylvania to develop new adeno associated virus (AAV) gene therapies.
New treatments for rare genetic diseases such as Pompe disease, Fabry disease, CDKL5 deficiency, and other rare metabolic disorders will be developed, under the collaboration.
Perelman School of Medicine will receive funding for the advancement of research programmes and licence technologies.
Based in the UK, Amicus Therapeutics is a biotechnology company focused on the development of therapeutics for rare and orphan diseases.
Janssen Pharmaceuticals has entered a $3.7bn licence and collaboration agreement with Arrowhead Pharmaceuticals to develop and commercialise a novel therapy candidate named ARO-HBV.
ARO-HBV is a RNAi candidate being developed for the treatment of chronic hepatitis B viral infection.
Janssen will receive the worldwide exclusive licence for the candidate, under the agreement. Arrowhead will complete the ongoing clinical studies, while Janssen will perform the further clinical development and commercialisation.
Based in Belgium, Janssen Pharmaceuticals is a pharmaceutical company, while Arrowhead Pharmaceuticals is a biopharmaceutical company based in the US.
Ionis Pharmaceuticals has collaborated with Roche for the development of the former’s IONIS-FB-LRX targeting Factor B for the treatment of complement-mediated diseases.
The companies will initially focus on the development of treatments for Geographic Atrophy, as part of the collaboration.
Ionis will receive an upfront payment of $75m and will be eligible to receive up to $684m as milestone payments and other royalties.
Based in the US, Ionis Pharmaceuticals is a pharmaceutical company focusing on RNA-targeted drug discovery and development, while Roche is a biotechnology company based in Switzerland.
Novan has expanded an initial a licence agreement signed with Sato Pharmaceutical to include the former’s topical nitric oxide-releasing candidate SB206 for the treatment of viral skin infections.
The previous agreement granted Sato with the license to develop and commercialise Novan’s SB204 to treat acne vulgaris in Japan.
The revised agreement grants Sato license to develop and commercialise SB206. Novan will receive an upfront payment of ¥1.25bn ($11m approximately) from Sato, under the agreement.
Novan and Sato Pharmaceuticals are pharmaceutical companies based in the US and Japan respectively.
